NCT02374853

Brief Summary

The purpose of this research is to determine if using the antibiotic vancomycin as a preventative topical (on the surface of the skin) treatment during open-heart surgery will reduce the risk of developing a sternal wound infection.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,037

participants targeted

Target at P75+ for phase_2

Timeline
Completed

Started Mar 2015

Typical duration for phase_2

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 23, 2015

Completed
6 days until next milestone

Study Start

First participant enrolled

March 1, 2015

Completed
1 day until next milestone

First Posted

Study publicly available on registry

March 2, 2015

Completed
4.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2019

Completed
3.6 years until next milestone

Results Posted

Study results publicly available

November 3, 2022

Completed
Last Updated

November 3, 2022

Status Verified

August 1, 2022

Enrollment Period

4.1 years

First QC Date

February 23, 2015

Results QC Date

August 17, 2022

Last Update Submit

November 1, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Number of Sternal Wound Infections

    The number of sternal wound infections at 3 months postoperative. This includes superficial incisional, deep incisional, and organ/space surgical site infections.

    3 months postoperative

Secondary Outcomes (5)

  • Number of Sternal Wound Infections

    1 year postoperative

  • Hospitalization

    1 year postoperative

  • Number of Participants With Use of Prophylactic Antibiotics

    Assessed before surgery

  • Cost Analysis for Sternal Wound Infection Treatment

    1 year postoperative

  • Adverse Events

    1 year postoperative

Study Arms (2)

Vancomycin

EXPERIMENTAL

During open heart surgery, patients will have a 4 x 8 inch piece of sterile gauze covering each side of the divided sternum. The gauze will be soaked in the following solution: 5 g vancomycin dissolved in 50 mL sterile water

Drug: Vancomycin

Control

PLACEBO COMPARATOR

During open heart surgery, patients will have a 4 x 8 inch piece of sterile gauze covering each side of the divided sternum. The gauze will be soaked in 50 mL sterile water. No Vancomycin

Other: No Vancomycin

Interventions

Topical prophylactic antibiotic

Also known as: Vancomycin Hydrochloride
Vancomycin

Placebo: Sterile water. No Vancomycin.

Also known as: Sterile water
Control

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Able to sign Informed Consent and Release of Medical Information Form
  • Age ≥ 18 years
  • Undergoing cardiac surgery with complete sternotomy (including re-operations)

You may not qualify if:

  • Evidence of active infection (any culture positive or blood positive infection)
  • Undergoing organ transplantation
  • Patients with known hypersensitivity to vancomycin
  • Pregnant or nursing women
  • Mental impairment or other conditions that may not allow participant to understand the nature, significance, and scope of study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Infections

Interventions

Vancomycin

Intervention Hierarchy (Ancestors)

GlycopeptidesGlycoconjugatesCarbohydratesPeptidesAmino Acids, Peptides, and Proteins

Results Point of Contact

Title
Dr. John Mullen
Organization
University of Alberta

Study Officials

  • Abbas Khani-Hanjani, MD

    University of Alberta

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 23, 2015

First Posted

March 2, 2015

Study Start

March 1, 2015

Primary Completion

April 1, 2019

Study Completion

April 1, 2019

Last Updated

November 3, 2022

Results First Posted

November 3, 2022

Record last verified: 2022-08